A Multicentre, Prospective, Randomized, Open Label, Blinded-Endpoint, Placebo-controlled, Single-dose Trial to Determine the Efficacy and Safety of NoNO-42 in Participants with Acute Ischemic Stroke Selected for Thrombolysis with or Without Endovascular Thrombectomy (ACT-42 Trial)

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).
This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.
A total of up to 600 male and female participants aged ≥ 45 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 3 hours of stroke onset/last known well.

开始日期2024-10-02

申办/合作机构

NoNO, Inc.

NCT06352632 / Recruiting临床3期IIT

A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

开始日期2024-09-26

申办/合作机构

The George Institute for Global Health

[+2]

NCT05636306 / Completed临床1期

A Phase 1, Randomized, Placebo Controlled, Double-Blind, Single Dose Escalation Study of NoNO-42 in Healthy Adults

The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of a single ascending intravenous dose of NoNO-42 administered to healthy adults.
Participants will be administered a single intravenous dose of NoNO-42 or placebo.
Participants will be confined for 24 hours post dose with a follow-up visit at Day 4 and Day 28.

开始日期2022-11-22

申办/合作机构

NoNO, Inc.

100 项与 NoNO-42 相关的临床结果

登录后查看更多信息

100 项与 NoNO-42 相关的转化医学

登录后查看更多信息

100 项与 NoNO-42 相关的专利（医药）

登录后查看更多信息

100 项与 NoNO-42 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑卒中	临床3期	澳大利亚	The George Institute for Global Health	2024-09-26
脑卒中	临床3期	加拿大	The George Institute for Global Health	2024-09-26
急性缺血性卒中	临床2期	加拿大	NoNO, Inc.	2024-10-02